Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Alexion Pharmaceuticals (ALXN) to Report a Decline in Earnings: What to Look Out for

Activision Blizzard

Baker Hughes Co

BioMarin Pharmaceutical

Esperion Therapeutics

Fate Therapeutics

Flexion Therapeutics

Reata Pharmaceuticals

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Alexion, Activision, Baker Hughes and More Monday Afternoon Analyst Calls

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.

Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?

Alexion Pharmaceuticals (ALXN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

Alexion Pharmaceuticals (ALXN) is Overbought: Is A Drop Coming?

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on May 3, 2021. Given the previously announced agreement to be acquired by AstraZeneca, Alexion will not be hosting a conference call. Earnings materials will be made available publicly on the Investor Relations page of our website at http://ir.alexion.com. Questions may be directe

Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021

AstraZeneca

AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.

AstraZeneca (AZN) Gets FTC Clearance for Alexion Acquisition

Alexion (ALXN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Alexion (ALXN) Moves 3.9% Higher: Will This Strength Last?

AstraZeneca PLC (LON:AZN) said its planned acquisition of rare disease specialist Alexion Pharmaceuticals Inc has been cleared by the US Federal Trade Commission. The FTSE 100 pharma giant said the approval follows similar clearances in Canada, Brazil, Russia and other countries globally, with additional regulatory clearances still pending from territories including the UK, the EU and Japan.

AstraZeneca receives green light from US regulators for Alexion acquisition

AbbVie

ACADIA Pharma

Biogen

BioNTech SE

CRISPR Therapeutics

Editas Medicine

Illumina

Kadmon Hlds

Moderna

Pfizer

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

SSR Mining

Patient investors can make bank from these well-run businesses.

3 Value Stocks That'll Make You Richer in Q2 (and Beyond)

DraftKings

GlaxoSmithKline

Southwest Airlines

Netflix

Burlington Stores

Inovio Pharmaceuticals

MongoDB

Snowflake

With the trading day about halfway over, the broad markets had pulled back slightly.

DraftKings, GlaxoSmithKline, Netflix, Southwest and More Tuesday Afternoon Analyst Calls

AstraZeneca stock jumped Tuesday after the company reaffirmed its plan to acquire Alexion Pharmaceuticals in the third quarter, even as more European countries suspended use of its Covid vaccine. The post AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt appeared first on Investor's Business Daily.

AstraZeneca Pops On Alexion Buyout Despite Mounting Covid Vaccine Doubt

Big Rock Partners

NEW YORK, March 12, 2021 /PRNewswire/ --                                         If you own shares in any of the companies listed above and                             would like to discuss our investigations or have any questions concerning                                       this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP1500 Broadway, 16th Floor New York, NY 10036 (212) 682-3025(888) 593-4771 stockinfo@weisslawllp.com Bank of Fincastle (OTCM: BFTL)WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Bank of Fincastle (OTCM: BFTL) in connection with the proposed acquisition of the company by First National Corporation ("First National").

SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, BRPA, and KTYB Shareholders About Its Ongoing Investigations

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock?

Why Is Alexion (ALXN) Down 3.5% Since Last Earnings Report?

BOSTON--(BUSINESS WIRE)--Alexion announces upcoming data presentations at the 73rd annual meeting of the American Academy of Neurology.

Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology

Star Peak Energy Transition Corp

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th Floor...

SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations

Cisco Systems

Mondelez

T-Mobile US

The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.

Nasdaq ETF's Worst Day Since October: Stocks That Survived

SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

Barrick Gold

Horizon Pharma

RealPage

Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Barrick Gold Corp. (NYSE:GOLD), Thryv Holdings Inc. (NASDAQ:THRY), Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and RealPage Inc. (NASDAQ:RP).

John Paulson's Top 5 Buys of the 4th Quarter

Celestica

Canadian Solar

Sanmina-SCI

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuticals (ALXN) boast low P/CF ratio.

Pick These 4 Low P/CF Stocks for a Value-Based Portfolio

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Albertsons Companies

AGCO

Pilgrim's Pride

Here are five of the 61 value stocks with discounted PEG.

5 Best PEG-Driven Value Stocks Amid COVID-Led Uncertainty

AECOM

Flex

MaxLinear

Top Ranked Growth Stocks to Buy for February 10th

Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.

Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates

Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Alexion Pharma Stock (ALXN)